Caseware UK (AP4) 2023.0.135 2023.0.135 2024-02-292024-02-2910falsetrue2023-03-01falseDispensing chemist in specialised stores12trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 07924165 2023-03-01 2024-02-29 07924165 2022-03-01 2023-02-28 07924165 2024-02-29 07924165 2023-02-28 07924165 c:Director1 2023-03-01 2024-02-29 07924165 d:Buildings d:LongLeaseholdAssets 2023-03-01 2024-02-29 07924165 d:Buildings d:LongLeaseholdAssets 2024-02-29 07924165 d:Buildings d:LongLeaseholdAssets 2023-02-28 07924165 d:PlantMachinery 2023-03-01 2024-02-29 07924165 d:PlantMachinery 2024-02-29 07924165 d:PlantMachinery 2023-02-28 07924165 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-03-01 2024-02-29 07924165 d:OwnedOrFreeholdAssets 2023-03-01 2024-02-29 07924165 d:Goodwill 2023-03-01 2024-02-29 07924165 d:Goodwill 2024-02-29 07924165 d:Goodwill 2023-02-28 07924165 d:CurrentFinancialInstruments 2024-02-29 07924165 d:CurrentFinancialInstruments 2023-02-28 07924165 d:Non-currentFinancialInstruments 2024-02-29 07924165 d:Non-currentFinancialInstruments 2023-02-28 07924165 d:CurrentFinancialInstruments d:WithinOneYear 2024-02-29 07924165 d:CurrentFinancialInstruments d:WithinOneYear 2023-02-28 07924165 d:Non-currentFinancialInstruments d:AfterOneYear 2024-02-29 07924165 d:Non-currentFinancialInstruments d:AfterOneYear 2023-02-28 07924165 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-02-29 07924165 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2023-02-28 07924165 d:ShareCapital 2024-02-29 07924165 d:ShareCapital 2023-02-28 07924165 d:RetainedEarningsAccumulatedLosses 2024-02-29 07924165 d:RetainedEarningsAccumulatedLosses 2023-02-28 07924165 d:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2023-03-01 2024-02-29 07924165 d:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2024-02-29 07924165 d:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2023-02-28 07924165 c:FRS102 2023-03-01 2024-02-29 07924165 c:AuditExempt-NoAccountantsReport 2023-03-01 2024-02-29 07924165 c:FullAccounts 2023-03-01 2024-02-29 07924165 c:PrivateLimitedCompanyLtd 2023-03-01 2024-02-29 07924165 2 2023-03-01 2024-02-29 07924165 d:AcceleratedTaxDepreciationDeferredTax 2024-02-29 07924165 d:AcceleratedTaxDepreciationDeferredTax 2023-02-28 07924165 d:OtherDeferredTax 2024-02-29 07924165 d:OtherDeferredTax 2023-02-28 07924165 d:Goodwill d:OwnedIntangibleAssets 2023-03-01 2024-02-29 07924165 e:PoundSterling 2023-03-01 2024-02-29 iso4217:GBP xbrli:pure

Registered number: 07924165










WEINRONK PHARMACIES LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 29 FEBRUARY 2024

 
WEINRONK PHARMACIES LIMITED
REGISTERED NUMBER: 07924165

STATEMENT OF FINANCIAL POSITION
AS AT 29 FEBRUARY 2024

29 February
28 February
2024
2023
Note
£
£

Fixed assets
  

Intangible assets
 4 
143,049
160,930

Tangible assets
 5 
47,822
61,229

  
190,871
222,159

Current assets
  

Stocks
  
36,567
44,499

Debtors: amounts falling due within one year
 6 
88,882
89,274

Cash at bank and in hand
 7 
149,813
193,764

  
275,262
327,537

Creditors: amounts falling due within one year
 8 
(132,481)
(120,889)

Net current assets
  
 
 
142,781
 
 
206,648

Total assets less current liabilities
  
333,652
428,807

Creditors: amounts falling due after more than one year
 9 
(150,965)
(203,703)

Provisions for liabilities
  

Deferred tax
 11 
(7,425)
(9,361)

Other provisions
 12 
(66,993)
(80,076)

  
 
 
(74,418)
 
 
(89,437)

Net assets
  
108,269
135,667

Page 1

 
WEINRONK PHARMACIES LIMITED
REGISTERED NUMBER: 07924165
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 29 FEBRUARY 2024

29 February
28 February
2024
2023
Note
£
£

Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
108,169
135,567

  
108,269
135,667


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 11 October 2024.






A Weinronk
Director

The notes on pages 3 to 11 form part of these financial statements.

Page 2

 
WEINRONK PHARMACIES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

1.


General information

The company is a private company limited by shares, which is incorporated under the Companies Act 2006 and registered in England (no.07924165). The address of the registered office is 4 Rathmore Drive, Prenton, Merseyside CH43 2HD.
These financial statements present information about the company as an individual undertaking. It is not a member of a group of companies. The principal activity of the company is the operation of a retail pharmacy.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The presentation currency of these financial statements is pound sterling; the financial statements are rounded to the nearest pound.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Going concern

The company has cash resources and has no requirement for external funding. The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. They continues to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Page 3

 
WEINRONK PHARMACIES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

2.Accounting policies (continued)

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.4

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.5

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.6

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 
WEINRONK PHARMACIES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

2.Accounting policies (continued)

 
2.7

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

 
2.8

Intangible assets

Goodwill

Goodwill represents the difference between amounts paid on the cost of a business combination and the acquirer’s interest in the fair value of its identifiable assets and liabilities of the acquiree at the date of acquisition. Subsequent to initial recognition, goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is amortised on a straight-line basis to the Statement of Comprehensive Income over its useful economic life.

Other intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 
2.9

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 5

 
WEINRONK PHARMACIES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

2.Accounting policies (continued)


2.9
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

L/Term Leasehold Property
-
10 years straight line
Plant & machinery
-
15 - 50% straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.10

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.11

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.12

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.13

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 6

 
WEINRONK PHARMACIES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

2.Accounting policies (continued)

 
2.14

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

 
2.15

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 12 (2023 - 10).


4.


Intangible assets






Goodwill

£



Cost


At 1 March 2023
357,622



At 29 February 2024

357,622



Amortisation


At 1 March 2023
196,692


Charge for the year on owned assets
17,881



At 29 February 2024

214,573



Net book value



At 29 February 2024
143,049



At 28 February 2023
160,930



Page 7

 
WEINRONK PHARMACIES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

5.


Tangible fixed assets







L/Term Leasehold Property
Plant & machinery
Total

£
£
£



Cost or valuation


At 1 March 2023
4,522
119,378
123,900


Additions
-
680
680


Disposals
-
(11,483)
(11,483)



At 29 February 2024

4,522
108,575
113,097



Depreciation


At 1 March 2023
4,522
58,149
62,671


Charge for the year on owned assets
-
14,087
14,087


Disposals
-
(11,483)
(11,483)



At 29 February 2024

4,522
60,753
65,275



Net book value



At 29 February 2024
-
47,822
47,822



At 28 February 2023
-
61,229
61,229

Page 8

 
WEINRONK PHARMACIES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

6.


Debtors

29 February
28 February
2024
2023
£
£


Trade debtors
73,491
71,592

Other debtors
10,436
8,717

Prepayments and accrued income
4,955
8,965

88,882
89,274



7.


Cash and cash equivalents

29 February
28 February
2024
2023
£
£

Cash at bank and in hand
149,813
193,764

149,813
193,764



8.


Creditors: Amounts falling due within one year

29 February
28 February
2024
2023
£
£

Trade creditors
118,713
110,187

Corporation tax
7,545
4,830

Other taxation and social security
2,568
2,279

Other creditors
655
593

Accruals and deferred income
3,000
3,000

132,481
120,889



9.


Creditors: Amounts falling due after more than one year

29 February
28 February
2024
2023
£
£

Other loans
150,965
203,703

150,965
203,703


Page 9

 
WEINRONK PHARMACIES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

10.


Loans


Analysis of the maturity of loans is given below:


29 February
28 February
2024
2023
£
£



Amounts falling due 2-5 years

Other loans
150,965
203,703


150,965
203,703


Page 10

 
WEINRONK PHARMACIES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024

11.


Deferred taxation






2024


£






At beginning of year
(9,361)


Charged to profit or loss
1,936



At end of year
(7,425)

The provision for deferred taxation is made up as follows:

29 February
28 February
2024
2023
£
£


Accelerated capital allowances
(7,443)
(9,374)

Short term timing differences
18
13

(7,425)
(9,361)


12.


Provisions






Pension annuity provision

£





At 1 March 2023
80,076


Charged to profit or loss
(4,083)


Utilised in year
(9,000)



At 29 February 2024
66,993


13.


Pension commitments

The Company pays into personal pension plans. The assets of the plans are held separately from those of the Company  in an independently administered fund. The pension cost charge represents contributions payable by the Company  to the plans and amounted to £1,082 (2023 - £1,100) . Contributions totalling £655 (2023 - £594) were payable to the fund at the balance sheet date and are included in creditors.

 
Page 11